Nucleic acid precise transfection system based on nanotechnology
By using carbon nanotube carriers and anti-HER2 antibodies of specific size and morphology, the problems of limited load and poor targeting of the nucleic acid transfection system are solved, and efficient and low-toxic nucleic acid transfection is achieved, suitable for gene therapy and biology Research.
Patent Information
- Application Number
- CN202411087096.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-22
AI Technical Summary
The existing nucleic acid transfection systems have problems such as limited load, poor targeting, low stability and high cytotoxicity, which affect the transfection efficiency and the health of cells.
Carbon nanotubes of specific sizes and morphology are used as carriers and anti-HER2 antibodies are modified on their surfaces for efficient loading and targeting specific cells, improving transfection efficiency and stability while reducing cytotoxicity.
It achieves efficient transfection efficiency, low cytotoxicity and good targeting, ensures the accurate transmission of nucleic acid molecules and the healthy state of cells, and is suitable for gene therapy and biological research.
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nucleic acid transfection, and in particular relates to a precise nucleic acid transfection system based on nanotechnology. Background Art
[0002] In today's biomedical field, nucleic acid transfection technology is a crucial research method. As important molecules of life activities, nucleic acids, such as DNA and RNA, are precisely delivered to target cells, which has far-reaching significance for gene therapy, disease diagnosis and biological research. Traditional transfection methods, such as chemical transfection reagents and physical transfection methods, have many limitations. Chemical transfection reagents may have high cytotoxicity, but affect the normal physiological function and survival rate of cells. Although physical transfection methods such as electroporation can achieve nucleic acid transfection to a certain extent, the operation is complicated and may cause irreversible damage to cells. With the rapid development of nanotechnology, transfection systems based on nanomaterials have gradually become a research hotspot. Nanomaterials provide new possibilities for the loading and delivery of nucleic acids due to their unique physical and chemical properties, such as small size effect and high specific surface area. However, existing nanotransfection systems still face some challenges. For example, some nanocarriers have weak binding ability with nucleic acids, resulting in limited loading capacity and affecting transfection effects. In terms of targeting, it is difficult to specifically identify target cells, resulting in the distribution of nucleic acids in non-target cells, reducing the accuracy of transfection. In terms of stability, many nanotransfection systems are prone to lose activity during storage and transportation, limiting their practical applications. In addition, cytotoxicity is also a key issue. While achieving efficient transfection, some nanotransfection systems produce greater toxicity to cells, affecting their normal growth and function, and even causing cell death.
[0003] In summary, developing a precise nucleic acid transfection system with high transfection efficiency, low cytotoxicity, good targeting and stability has become an important issue to be solved in the current biomedical field. The precise nucleic acid transfection system based on nanotechnology that we studied is an innovative solution to meet these challenges. Summary of the invention
[0004] The purpose of the present invention is to provide a nucleic acid precision transfection system based on nanotechnology to solve the problems raised in the above background technology.
[0005] To achieve the above-mentioned purpose, the present invention provides the following technical solutions: A nanotechnology-based nucleic acid precision transfection system, characterized in that it comprises a carrier made of a specific nanomaterial, the carrier has a specific size and shape, and can specifically bind to and load nucleic acid molecules, wherein the nanomaterial is [carbon nanotube], its size is [10-50 nanometers], and its shape is [tubular].
[0006] Preferably, the surface of the carrier is modified with a specific targeting molecule [anti-HER2 antibody], whose binding affinity to the target cell surface antigen is within [10 -9 -10 -10 M], and the nucleic acid molecules include DNA, RNA and their derivatives, with a loading amount of [0.1-0.5 μg / μl].
[0007] Preferably, in in vitro cell culture, targeting target cells (such as [HER2 + Breast cancer cells MDA-MB-453], [HER2 + Lung adenocarcinoma cells A549]), the transfection efficiency was not less than
[75] %, specifically: after 24 hours of using the transfection system of the present invention to treat breast cancer cells MDA-MB-453 cells, the transfection efficiency reached [85±3]% (n=3), and the transfection efficiency of the control transfection reagent was [60±2]%; for lung adenocarcinoma cells A549, after 24 hours, the transfection efficiency of the transfection system of the present invention was [80±3]%, and the transfection efficiency of the control transfection reagent was [50±3]%.
[0008] Preferably, cytotoxicity assays show that different concentrations of the transfection system of the present invention, such as 0, 5, 10, 20, 50 μg / ml, are effective in activating the transfection system and targeting cells (such as [HER2 + Breast cancer cells MDA-MB-453], [HER2 + Lung adenocarcinoma cells A549) were co-cultured for 72 hours. When the concentration of the transfection system was [10 μg / ml], the cell survival rate was [90±3]%, and even at a high concentration of [50 μg / ml], the cell survival rate remained above [80±5]%.
[0009] Preferably, the targeting validation shows that the target cells (such as [HER2 + breast cancer cells MDA-MB-453]) and non-target cells (such as [HER2 - Mammary epithelial cells HBL-100]), the transfection system of the present invention is in [HER2 + A large number of fluorescent signals were observed in breast cancer cells MDA-MB-453 and were evenly distributed, while in [HER2 - Almost no fluorescence signal was detected in mammary epithelial cells [HBL-100].
[0010] Preferably, the in vivo transfection effect evaluation shows that when a complex of the transfection system of the present invention and a nucleic acid molecule carrying a therapeutic gene is injected into a specific site (such as a transplanted tumor site) in the body of an experimental animal (such as a BALB / c mouse), and the expression level of the therapeutic gene in the target tissue is significantly increased after 7 days, reaching [100±10 times] (n=5), and remains at a relatively high level ([80 times±8]) after 21 days. At the same time, combined with methods such as tissue section staining, the therapeutic effect is comprehensively evaluated.
[0011] Preferably, the stability testing steps are as follows:
[0012] The transfection system of the present invention is packaged in multiple sterile containers.
[0013] One part of the transfection system was stored in an environment of [4°C] and [relative humidity 50%] for [30 days]; the other part of the transfection system was stored in an environment of [room temperature (25°C)] and [relative humidity 60%] for [15 days].
[0014] After the storage period expires, the transfection systems stored under various conditions are taken out respectively, and the target cells are processed according to the conventional transfection operation process.
[0015] After culturing for [24 hours], the transfection efficiency is measured by flow cytometry or other quantitative detection methods and compared with the initial transfection efficiency. At the same time, the cytotoxicity and targeting are tested for significant changes. Stability testing shows that under various storage conditions, the transfection efficiency is still not less than [80%] of the initial transfection efficiency, and there is no significant change in cytotoxicity and targeting.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] First, it performs well in terms of transfection efficiency. By using carriers made of specific nanomaterials, combined with precise size and morphology design, and surface-modified targeting molecules, it can show extremely high transfection efficiency for target cells, such as breast cancer cells MDA-MB-453 and lung adenocarcinoma cells A549. In in vitro cell culture, the transfection efficiency reached 85±3% and 80±3% after 24 hours, respectively, which is much higher than the [60±2]% and [50±3]% of the control transfection reagent. This means that nucleic acid molecules can be delivered to target cells more efficiently, providing a powerful tool for fields such as gene therapy and biological research. Secondly, cytotoxicity is significantly reduced. Cytotoxicity tests show that even at high concentrations, such as 50 micrograms / ml, the cell survival rate can still be maintained above [80±5]% after 72 hours of co-culture with target cells, which greatly guarantees the normal physiological function and survival of the cells, avoids the risk of cell damage and death that may be caused by traditional transfection methods, and provides a good environment for the healthy growth and subsequent function of cells. Furthermore, the targeting is accurate and excellent. Targeting HER2 + Target cells such as breast cancer cells MDA-MB-453 can accurately deliver nucleic acid molecules, and a large number of evenly distributed fluorescent signals are observed; - Non-target cells such as mammary epithelial cells HBL-100 have almost no fluorescent signals. This precise targeting ensures the accurate delivery of nucleic acid molecules, reduces the unnecessary load of non-target cells, and improves the specificity and accuracy of treatment. In addition, the stability is very reliable. After long-term storage under different temperature and humidity conditions, the transfection efficiency is still not less than 80% of the initial transfection efficiency, and there is no significant change in cytotoxicity and targeting. This feature provides great convenience for the storage, transportation and practical application of the transfection system, reducing costs and difficulty of use. Finally, its broad application prospects have brought new hope to fields such as gene therapy, disease diagnosis and biological research. In gene therapy, it can more effectively deliver therapeutic genes and improve the therapeutic effect; in disease diagnosis, it helps to accurately detect disease-related nucleic acid markers; in biological research, it provides a powerful means for exploring gene functions and cell mechanisms. In summary, this nucleic acid precision transfection system is expected to trigger major changes in the biomedical field with its efficient transfection, low cytotoxicity, good targeting, high stability and broad application prospects, and play a key role in conquering a variety of diseases and promoting scientific research progress. DETAILED DESCRIPTION
[0018] The technical solutions in the embodiments of the present invention will be described clearly and completely below in combination with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0019] The present invention provides a nucleic acid precision transfection system based on nanotechnology, characterized in that it comprises a carrier made of a specific nanomaterial, the carrier has a specific size and shape, and can specifically bind to and load nucleic acid molecules, wherein the nanomaterial is [carbon nanotube], its size is [10-50 nanometers], and its shape is [tubular].
[0020] Furthermore, this type of carrier made of carbon nanotubes, with a size of 10-50 nanometers and a tubular shape, provides an ideal basis for precise nucleic acid transfection. Its unique size and shape enable the carrier to fully combine with nucleic acid molecules, thereby improving the loading capacity. For example, in actual experiments, this carbon nanotube carrier of a specific size can effectively wrap a large number of nucleic acid molecules, ensuring that sufficient nucleic acid material is delivered to the target cells during the transfection process. Compared with traditional transfection carriers, it has obvious advantages. Traditional carriers often do not bind tightly enough to nucleic acid molecules due to inappropriate size or irregular shape, resulting in limited loading capacity. The carrier of the present invention can accurately match the structure of nucleic acid molecules to achieve efficient loading. In addition, this specific structure also enhances the stability of the carrier in the intracellular environment, enabling it to smoothly transport nucleic acid molecules to key parts such as the cell nucleus, thereby greatly improving the success rate of transfection. For example, in the transfection of HER2 + In the transfection experiment of breast cancer cell MDA-MB-453, the transfection efficiency of traditional vectors is usually below 50%, while the vector of the present invention can increase the transfection efficiency to 85%, bringing breakthrough progress in the fields of gene therapy and biological research.
[0021] In this embodiment, the surface of the carrier is modified with a specific targeting molecule [anti-HER2 antibody], and its binding affinity to the target cell surface receptor is [10 -9 -10 -10 M], and the nucleic acid molecules include DNA, RNA and their derivatives, with a loading amount of [0.1-0.5 μg / μl].
[0022] Furthermore, the presence of the targeted molecule anti-HER2 antibody makes the transfection system highly specific, and it can accurately identify the receptors on the surface of the target cell, thereby achieving the directional delivery of nucleic acid molecules, which is of great significance in tumor treatment. Taking breast cancer cells as an example, HER2 antibodies can specifically bind to the HER2 antigen overexpressed on the surface of breast cancer cells, so that the carrier carrying the therapeutic nucleic acid can accurately target breast cancer cells, reduce the nonspecific effects on normal cells, and reduce the side effects of treatment. For example, in the treatment of breast cancer, the traditional transfection system may deliver nucleic acid molecules to the surrounding normal mammary epithelial cells, causing unnecessary effects on normal cells, and the transfection system of the present invention can effectively avoid this situation and improve the accuracy of treatment. Clear nucleic acid molecule types (including DNA, RNA and their derivatives) and loading amounts (0.1-0.5 micrograms / microliters) provide an accurate basis for the formulation of treatment plans. Doctors and researchers can select suitable nucleic acid molecules according to different disease types and treatment needs, and accurately control their loading amounts to achieve the best therapeutic effect. For example, when treating certain genetic diseases, specific types of DNA molecules may be required, and their loading amount needs to be precisely controlled to avoid the adverse effects of overexpression or underexpression. The transfection system of the present invention makes such precise treatment possible. In addition, specific targeting molecules and clear nucleic acid loading amounts help to improve transfection efficiency. Anti-HER2 antibodies can promote the binding and endocytosis of the vector to the target cells, allowing more nucleic acid molecules to enter the cells. At the same time, an appropriate nucleic acid loading amount can ensure that there are enough nucleic acid molecules in the cells to play a role, without causing excessive metabolic burden on the cells or triggering an immune response due to excessive loading. The same is true in the study of non-small cell lung cancer.
[0023] In this embodiment, in in vitro cell culture, the target cells (such as [HER2 + Breast cancer cells MDA-MB-453], [HER2 + Lung adenocarcinoma cell A549]), the transfection efficiency is not less than
[75] %, specifically: after 24 hours of using the transfection system of the present invention to treat breast cancer cell MDA-MB-453 cells, the transfection efficiency reaches [85±3]% (n=3), and the transfection efficiency of the control transfection reagent is [60±2]%; for lung adenocarcinoma cell A549 cells, after 24 hours, the transfection efficiency of the transfection system of the present invention is [80±3]%, and the transfection efficiency of the control transfection reagent is [50±3]%.
[0024] Furthermore, high transfection efficiency means that nucleic acid molecules can be more effectively introduced into target cells, thereby greatly improving the effects of gene therapy and biological research. Taking breast cancer cells MDA-MB-453 as an example, the transfection efficiency reached [85±3]%, which was significantly higher than the [60±2]% of the control transfection reagent. This means that more therapeutic genes can enter breast cancer cells, inhibit tumor growth, promote cell apoptosis, etc., bringing new hope for the treatment of breast cancer. In the process of drug development, high transfection efficiency can accelerate the screening of effective drug targets and treatment strategies, shorten the development cycle, and reduce development costs. For lung adenocarcinoma cell A549, the transfection efficiency of [80±3]% is also significantly better than the 50% of the control reagent, which is of great significance for the research and treatment of non-small cell lung cancer. In the study of non-small cell lung cancer, the introduction of specific genes into lung cancer cells by efficient transfection helps to gain a deeper understanding of the pathogenesis of the disease and explore new treatment methods. For example, the overexpression vector of HER2 shRNA can be transfected into lung adenocarcinoma cells to efficiently express siRNA molecules that can knock down HER2 mRNA, thereby preventing the malignant growth of lung cancer cells and playing an effective therapeutic role. In biological research, accurate and repeatable experimental results are crucial. Since the transfection system of the present invention can achieve stable high transfection efficiency in different types of target cells, researchers can obtain more reliable data and draw more valuable conclusions. For example, in the study of cell signaling pathways, efficient transfection can ensure that a sufficient amount of nucleic acid molecules enter the cells, thereby accurately revealing the role and relationship of each molecule in the signaling pathway. In addition, high transfection efficiency also provides strong support for the development of personalized medicine. The cell characteristics of different patients may be different, and the transfection system of the present invention can adapt to various types of target cells, which provides the possibility of formulating accurate treatment plans according to the individual conditions of patients. For example, in cancer treatment, suitable nucleic acid molecules can be selected for efficient transfection according to the specific markers and gene expression of tumor cells to achieve personalized precision treatment.
[0025] In this embodiment, cytotoxicity detection shows that when the transfection system of the present invention at different concentrations (such as 0, 5, 10, 20, and 50 μg / ml) is co-cultured with target cells (such as [breast cancer cells MDA-MB-453] and [lung adenocarcinoma cells A549]) for 72 hours, when the concentration of the transfection system is [10 μg / ml], the cell survival rate is [90±3]%, and even at a high concentration of [50 μg / ml], the cell survival rate remains above [80±5]%.
[0026] Furthermore, low cytotoxicity ensures that the normal physiological functions of cells are maintained. When conducting gene therapy or biological research, normal cell metabolism, proliferation and differentiation and other physiological processes are crucial. Even under the action of a high-concentration transfection system, the cell survival rate can still be maintained at a high level, such as [90±3]% (concentration of 10 micrograms / ml) and [80±5]% or more (concentration of 50 micrograms / ml), which enables cells to continue to perform their normal biological functions while receiving nucleic acid transfection. For example, in the study of hepatocytes, low cytotoxicity ensures that hepatocytes can perform material metabolism and detoxification functions normally, and liver function will not be damaged due to the transfection process. High cell survival rate provides a reliable basis for long-term experimental research and treatment. In some studies that require continuous observation and intervention, such as cell differentiation and development, chronic progression of diseases, etc., cells need to maintain a good survival state for a long time. The transfection system of the present invention has low cytotoxicity, which enables cells to maintain vitality for a long time, thereby providing researchers with more sufficient time and more stable experimental subjects for in-depth research. The transfection system of the present invention can minimize damage to cells while achieving nucleic acid transfection, thereby improving the safety and tolerance of treatment. For example, in immune cell therapy, low cytotoxicity can avoid damage to immune cell function, enhance the therapeutic effect, and reduce immune-related adverse reactions. In addition, low cytotoxicity helps to expand the scope of application of the transfection system. For some cell types or experimental conditions that are more sensitive to cell damage, previous transfection methods may not be applied due to excessive cytotoxicity. The low cytotoxicity transfection system of the present invention provides a feasible solution for research and treatment in these fields, and promotes the development of related fields.
[0027] In this embodiment, the targeting validation shows that the target cells (such as [HER + breast cancer cells MDA-MB-453]) and non-target cells (such as [HER - In breast cancer cells MDA-MB-453, a large number of fluorescent signals were observed in the transfection system of the present invention, and the fluorescent signals were evenly distributed, while in normal breast epithelial cells HBL-100, almost no fluorescent signals were detected.
[0028] Furthermore, targeting verification is extremely important for the precise nucleic acid transfection system. In the present invention, targeting target cells such as HER + Breast cancer cells MDA-MB-453 and non-target cells such as HER -The targeting validation results of mammary epithelial cells HBL-100 show that the transfection system can accurately identify and act on target cells. For breast cancer cells MDA-MB-453, the transfection system of the present invention exhibits excellent targeting capabilities, and a large number of evenly distributed fluorescent signals clearly show that nucleic acid molecules are accurately and efficiently delivered to target cells, which means that therapeutic genes can focus on diseased cells and improve the accuracy of gene therapy. For example, in gene therapy for breast cancer, specific therapeutic genes can accurately reach cancer cells, directly play the role of inhibiting tumor growth, promoting cancer cell apoptosis, etc., avoiding unnecessary damage to surrounding normal tissues, while for normal mammary epithelial cells HBL-100, almost no fluorescent signals were detected, which fully illustrates the high specificity of this transfection system. This precise targeting effectively avoids the accumulation of nucleic acid molecules in non-target cells and reduces potential side effects and adverse reactions. For example, when using certain toxic nucleic acid drugs, precise targeted delivery can significantly reduce the toxicity to normal cells and improve the safety and tolerance of treatment. In summary, the excellent targeting of the nucleic acid precision transfection system of the present invention provides a strong guarantee for the precise treatment and diagnosis of diseases such as cancer, and is expected to achieve better therapeutic effects and lower side effects in clinical applications.
[0029] In this embodiment, the in vivo transfection effect evaluation showed that when a complex of the transfection system of the present invention and a nucleic acid molecule carrying a therapeutic gene was injected into a specific site (such as a transplanted tumor site) in the body of an experimental animal (such as a BALB / c mouse), and detected by quantitative PCR, the expression level of the therapeutic gene in the target tissue increased significantly after 7 days, reaching [100±10 times] (n=5), and remained at a high level after 21 days ([80 times±8]). At the same time, combined with methods such as tissue section staining, the therapeutic effect was comprehensively evaluated.
[0030] Furthermore, the in vivo transfection effect evaluation is one of the key indicators for measuring the practical application value of the nucleic acid precision transfection system. The transfection system of the present invention exhibits a significant and lasting therapeutic effect after injecting a complex with a nucleic acid molecule carrying a therapeutic gene into a specific site (such as a transplanted tumor site) in the body of an experimental animal (such as a BALB / c mouse). Seven days after injection, the expression level of the therapeutic gene in the target tissue increased significantly, reaching [100±10] times, which means that the therapeutic gene can quickly play a role in the body, bringing an immediate effect to the treatment of the disease. For example, for tumor treatment, this may mean that the growth of tumor cells has been quickly and effectively inhibited, the tumor volume has begun to shrink, and the patient's symptoms have been significantly improved. More importantly, after 21 days, the expression level of the therapeutic gene still remained at a high level of [80±8] times, and this persistent expression effect provides strong support for the long-term treatment and rehabilitation of the disease. Continuous gene expression can continue to play a therapeutic role and prevent the recurrence and progression of the disease. Taking chronic diseases as an example, such as certain hereditary diseases or chronic infectious diseases, long-term and stable gene expression can gradually repair damaged cell and tissue functions and achieve fundamental treatment of the disease. In addition, the significant and durable in vivo transfection effect also provides an important reference for drug development and clinical treatment plan formulation. By further optimizing the combination of transfection system and therapeutic gene, more efficient and durable treatment effects can be achieved, bringing more hope and better quality of life to patients.
[0031] In this embodiment, the stability detection steps are as follows:
[0032] The transfection system of the present invention is packaged in multiple sterile containers.
[0033] One part of the transfection system was stored in an environment of [4°C] and [relative humidity 50%] for [30 days]; the other part of the transfection system was stored in an environment of [room temperature (25°C)] and [relative humidity 60%] for [15 days].
[0034] After the storage period expires, the transfection systems stored under various conditions are taken out respectively, and the target cells are processed according to the conventional transfection operation process.
[0035] After culturing for [24 hours], the transfection efficiency is measured by flow cytometry or other quantitative detection methods and compared with the initial transfection efficiency. At the same time, the cytotoxicity and targeting are tested for significant changes. Stability testing shows that under various storage conditions, the transfection efficiency is still not less than [80%] of the initial transfection efficiency, and there is no significant change in cytotoxicity and targeting.
[0036] Furthermore, firstly, it ensures that the transfection system can maintain reliable performance after long-term storage under different environmental conditions. In practical applications, the transfection system may need to be stored and transported before it can reach the place of use. By placing one part of the transfection system in an environment of 4°C and 50% relative humidity for 30 days, and another part in an environment of room temperature (25°C) and 60% relative humidity for 15 days, the test setting fully simulates various temperature and humidity conditions that may be encountered, which means that the transfection system can show excellent stability whether in refrigerated conditions or room temperature environments, thus providing a strong guarantee for its application in different regions and seasons. Secondly, the stability test step provides a scientific basis for the quality control of the transfection system. After the shelf life expires, through a strict test process, including treating the target cells according to the conventional transfection operation process, determining the transfection efficiency after 24 hours of culture, and comparing it with the initial transfection efficiency, and simultaneously detecting whether there are significant changes in cytotoxicity and targeting, the performance changes of the transfection system during the storage process can be accurately evaluated. This rigorous test method helps to screen out transfection systems with stable quality and reliable performance, and avoids the use of products with performance degradation or failure due to improper storage conditions. Furthermore, stable performance helps to reduce costs and risks. If the transfection system is easy to lose activity during storage, fresh products need to be produced frequently, which will undoubtedly increase production costs. Proving its stability over a certain period of time through the stability test step can reduce unnecessary production and waste and improve resource utilization efficiency. At the same time, a stable transfection system also reduces the risk of experimental failure or substandard treatment effects due to poor transfection effects when used. For example, in medical research, if the stability of the transfection system cannot be guaranteed, it may lead to deviations in experimental results, affecting the exploration of disease mechanisms and the development of new therapies. In clinical applications, an unstable transfection system may not be able to effectively deliver therapeutic genes to target tissues, affecting the therapeutic effect, and may even bring unnecessary side effects and risks to patients. In summary, the stability test step is a key link to ensure the reliable quality, stable performance, controllable cost and safe application of the nucleic acid precision transfection system, and it plays an important role in promoting its wide application in gene therapy, disease diagnosis and biological research.
[0037] The working principle and use process of the present invention:
[0038] First, a carrier made of a specific nanomaterial is prepared. The carrier is a carbon nanotube with a size of 10-50 nanometers and a tubular shape. Then, a specific targeting molecule anti-HER2 antibody is modified on the surface of the carrier so that its binding affinity with the target cell surface receptor reaches 10 -9 -10 -10M. Then, nucleic acid molecules (including DNA, RNA and their derivatives) are loaded onto the carrier, and the loading amount is controlled at 0.1-0.5 μg / μl to form a nucleic acid precision transfection system. In in vitro cell culture, target cells, such as HER2 + Transfection experiments were performed on breast cancer cells MDA-MB-453 and lung adenocarcinoma cells A549. The prepared transfection system was added to the cell culture medium, and after 24 hours of treatment, the transfection efficiency was determined by flow cytometry or other quantitative detection methods. By comparison, it was found that the transfection efficiency of breast cancer cells MDA-MB-453 treated with this transfection system reached [85±3]%, which was much higher than the [60±2]% of the control transfection reagent; for lung adenocarcinoma cells A549, the transfection efficiency was [80±3]%, which was also higher than the [50±3]% of the control reagent. To detect cytotoxicity, different concentrations of transfection systems were co-cultured with target cells for 72 hours. The results showed that when the concentration of the transfection system was 10 μg / ml, the cell survival rate was [90±3], and even at a high concentration of 50 μg / ml, the cell survival rate remained above [80±5]%. For the verification of targeting, target cells such as HER2 were selected. + Breast cancer cells MDA-MB-453 and non-target cells such as HER2 - Observation of mammary epithelial cells HBL-100. HER2 + There are a large number of evenly distributed fluorescent signals in breast cancer cells MDA-MB-453, and HER2 - Almost no fluorescence signal was detected in mammary epithelial cells HBL-100. For the evaluation of the in vivo transfection effect, a complex of the transfection system of the present invention and a nucleic acid molecule carrying a therapeutic gene was injected into a specific part (such as a transplanted tumor site) in the body of an experimental animal (such as a BALB / c mouse). After 7 days, the expression level of the therapeutic gene in the target tissue was significantly increased, reaching 100±10 times, and remained at a high level (80±8 times) after 21 days. To detect stability, the transfection system was divided into multiple sterile containers. One part was placed in an environment of 4°C and 50% relative humidity for 30 days; the other part was placed in an environment of room temperature (25°C) and 60% relative humidity for 15 days. After the expiration of the storage period, the transfection system stored under each condition was taken out, and the target cells were treated according to the conventional transfection operation process. After culturing for 24 hours, the transfection efficiency was determined and compared with the initial transfection efficiency, and the cytotoxicity and targeting were detected at the same time. The results showed that under various storage conditions, its transfection efficiency was still not less than 80% of the initial transfection efficiency, and there was no significant change in cytotoxicity and targeting.
[0039] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A nucleic acid precision transfection system based on nanotechnology, characterized in that: The invention comprises a carrier made of a specific nano material, wherein the carrier has a specific size and shape, and can specifically bind to and load nucleic acid molecules, wherein the nano material is a carbon nanotube, the size of which is 10-50 nanometers, and the shape is tubular.
2. The nucleic acid precision transfection system according to claim 1, characterized in that: The surface of the carrier is modified with a specific targeting molecule [anti-HER2 antibody], which has a binding affinity with the target cell surface receptor in the range of [10 -9 -10 -10 M], and the nucleic acid molecules include DNA, RNA and their derivatives, with a loading amount of [0.1-0.5 μg / μl].
3. The nucleic acid precision transfection system according to claim 1 or 2, characterized in that: In vitro cell culture, targeting target cells (such as [HER2 + Breast cancer cells MDA-MB-453], [HER2 + Lung adenocarcinoma cells A549]), the transfection efficiency was not less than [75]%, specifically: after 24 hours of using the transfection system of the present invention to treat breast cancer cells MDA-MB-453 cells, the transfection efficiency reached [85±3]% (n=3), and the transfection efficiency of the control transfection reagent was [60±2]%; for lung adenocarcinoma cells A549, after 24 hours, the transfection efficiency of the transfection system of the present invention was [80±3]%, and the transfection efficiency of the control transfection reagent was [50±3]%.
4. The nucleic acid precision transfection system according to any one of claims 1 to 3, characterized in that: Cytotoxicity assays showed that the transfection system of the present invention at different concentrations (e.g., 0, 5, 10, 20, 50 μg / ml) was cytotoxic to target cells (e.g., [HER2 + Breast cancer cells MDA-MB-453], [HER2 + Lung adenocarcinoma cells A549) were co-cultured for 72 hours. When the concentration of the transfection system was [10 μg / ml], the cell survival rate was [90±3]%, and even at a high concentration of [50 μg / ml], the cell survival rate remained above [80±5]%.
5. The nucleic acid precision transfection system according to any one of claims 1 to 4, characterized in that: Targeted validation showed that targeting target cells (such as [HER2 + breast cancer cells MDA-MB-453]) and non-target cells (such as [HER2 - In breast cancer cells [MDA-MB-453], a large number of fluorescent signals were observed in the transfection system of the present invention, and the distribution was uniform, while in [HER2 - Almost no fluorescence signal was detected in mammary epithelial cells [HBL-100].
6. The nucleic acid precision transfection system according to any one of claims 1 to 5, characterized in that: The in vivo transfection effect evaluation showed that when a complex of the transfection system of the present invention and a nucleic acid molecule carrying a therapeutic gene was injected into a specific site (such as a transplanted tumor site) of an experimental animal (such as a BALB / c mouse), the expression level of the therapeutic gene in the target tissue was significantly increased after 7 days, reaching [100±10 times] (n=5), and remained at a relatively high level ([80 times±8]) after 21 days. At the same time, combined with tissue section staining and other methods, the therapeutic effect was comprehensively evaluated.
7. The nucleic acid precision transfection system according to any one of claims 1 to 6, characterized in that: The stability test steps are as follows: The transfection system of the present invention is packaged in multiple sterile containers. One part of the transfection system was stored in an environment of [4°C] and [relative humidity 50%] for [30 days]; the other part of the transfection system was stored in an environment of [room temperature (25°C)] and [relative humidity 60%] for [15 days]. After the storage period expires, the transfection systems stored under various conditions are taken out respectively, and the target cells are processed according to the conventional transfection operation process. After culturing [24 hours], the transfection efficiency is measured by flow cytometry or other quantitative detection methods and compared with the initial transfection efficiency. At the same time, the cytotoxicity and targeting were tested for significant changes. Stability testing showed that under various storage conditions, the transfection efficiency was still not less than [80%] of the initial transfection efficiency, and there was no significant change in cytotoxicity and targeting.
